Aireen is an innovative AI-powered medical device dedicated to transforming how healthcare providers detect and manage serious diseases. By leveraging advanced neural network models, Aireen enables autonomous, precise screening for conditions such as diabetic retinopathy (DR), age-related macular degeneration (AMD), cardiovascular diseases, and neurodegenerative disorders. Why Aireen? Diabetic retinopathy alone affects nearly 30% of the global diabetic population, and with over 537 million people living with diabetes today—a number projected to reach 783 million by 2045—the need for accurate, scalable screening solutions has never been greater. Early detection is key to preventing severe complications like vision loss. Aireen empowers healthcare providers by offering fast, reliable AI-driven analysis without the need for manual interpretation, ensuring critical conditions are identified at their earliest stages. Key Benefits: Autonomous AI Screening: Aireen functions independently, requiring no human intervention in analyzing retinal images, reducing the risk of human error and improving efficiency. Certified for Precision: CE-certified as a Class IIb medical device, Aireen meets the highest safety and performance standards, developed with input from top ophthalmologists and internal medicine experts. Expanding Capabilities: Beyond DR and AMD, Aireen is evolving to include diagnostic tools for cardiovascular and neurodegenerative diseases, addressing the growing demand for comprehensive early disease detection in multiple fields of medicine. Data Security and Compliance: Aireen prioritizes patient data safety, with GDPR compliance and the ability to create local cloud instances to meet regional data regulations. A Solution for Today’s Healthcare Needs Aireen is designed to integrate seamlessly into existing workflows, requiring minimal training and providing quick results to healthcare teams. It empowers clinics and hospitals to scale their screening efforts.